Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
Exagen Inc. (XGN) Announces Preliminary Financial Results and Reaffirms Full-Year 2023 Guidance
Positive
Record AVISE® CTD testing volume of approximately 137,000 units delivered during the year ended December 31, 2023.
Cash balance of $36.5 million as of December 31, 2023.
Reaffirms full-year 2023 total revenue guidance of at least $50 million and full-year 2023 non-GAAP adjusted EBITDA guidance of approximately negative $20 million.
Negative
Non-GAAP financial measure used in the press release may impact the calculation of GAAP net loss.
The company's final results may vary from the preliminary results presented due to ongoing financial closing procedures.
The announcement by Exagen Inc. of its preliminary unaudited financial results, along with the reaffirmation of its 2023 financial guidance, is a significant indicator of the company's operational performance and financial health. The reported record AVISE® CTD testing volume signifies a robust demand for the company's autoimmune testing solutions, which could be seen as a positive driver for revenue growth. A cash balance of $36.5 million provides a cushion for operational expenses and indicates a potentially stable financial position. However, the forecast of a non-GAAP adjusted EBITDA of approximately negative $20 million warrants a cautious approach, as it suggests that the company is still navigating through losses.
Investors should note that the use of non-GAAP financial measures, such as adjusted EBITDA, can provide a more nuanced understanding of a company's operational efficiency by excluding non-cash expenses and certain variable items. However, these measures should be considered alongside GAAP results, as they may exclude significant expenses that affect a company's actual financial condition. The absence of a reconciliation of adjusted EBITDA to net loss may limit the transparency and comparability of Exagen's financial guidance.
Exagen's reaffirmation of its revenue guidance at a minimum of $50 million suggests confidence in its market positioning and product demand, particularly for its AVISE® CTD testing. The emphasis on anticipated growth in Average Selling Price (ASP) and volume for the upcoming year could indicate a strategic focus on both market penetration and margin improvement. The company's ability to successfully navigate the competitive landscape of autoimmune testing solutions will be critical in achieving these goals.
It is also important to consider industry trends, such as the increasing prevalence of autoimmune diseases and the growing importance of personalized medicine, which could benefit Exagen. The company's performance should be evaluated in the context of these market dynamics, as well as potential regulatory changes that could affect the industry.
The reported increase in AVISE® CTD testing volume reflects Exagen's operational success in meeting the clinical demand for autoimmune diagnostics. This growth is indicative of the company's effective market strategies and the potential clinical value of its testing solutions. The impact on the healthcare sector could be significant if Exagen's tests lead to improved patient outcomes through earlier and more accurate diagnosis of autoimmune conditions.
However, investors should consider the research and development implications of such growth. Continuous investment in innovation is essential to maintain competitiveness in the biotechnology and diagnostics industry. Exagen's future R&D commitments and their alignment with emerging healthcare trends will be crucial in sustaining long-term growth and addressing unmet medical needs.
01/07/2024 - 12:00 PM
CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance.
Select Preliminary Unaudited Financial Results
Record AVISE® CTD testing volume of approximately 137,000 units delivered during the year ended December 31, 2023. Cash balance of $36.5 million as of December 31, 2023. Accounts receivables balance of approximately $7 million as of December 31, 2023. Reaffirms Financial Guidance
The company reaffirms its full-year 2023 total revenue guidance of at least $50 million and full-year 2023 non-GAAP adjusted EBITDA guidance of approximately negative $20 million . “I’m very proud of the strides the Exagen team made in 2023. Our company has undergone a significant transformation, now operating in a more streamlined manner with a revamped expense structure that points us toward profitability. The unwavering dedication and hard work of our team has laid the foundation for an exciting 2024 where we anticipate seeing growth in both ASP and volume of AVISE® CTD,” said John Aballi, President and Chief Executive Officer of Exagen.
Cautionary Note Regarding Select Preliminary Unaudited Financial Results
The company is providing the above preliminary financial information and results of operations as of and for the year ended December 31, 2023, based on currently available information. The company’s financial closing procedures with respect to the estimated financial data provided above are not yet complete. These procedures often result in changes to accounts. As a result, the company’s final results may vary from the preliminary results presented above. The company undertakes no obligation to update or supplement the information provided above until it releases its financial statements for the three months and year ended December 31, 2023.
Use of Unaudited Non-GAAP Financial Measures
In addition to the financial results prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), this press release contains the metric adjusted EBITDA, which is not calculated in accordance with GAAP and is a non-GAAP financial measure. Adjusted EBITDA excludes from net loss interest income (expense), income tax expense (benefit), depreciation and amortization expense, and stock-based compensation expense. Such items could have a significant impact on the calculation of GAAP net loss. The company is not able to provide a quantitative reconciliation of its full-year 2023 adjusted EBITDA guidance to net loss, the most directly comparable GAAP measure, and has not provided forward-looking guidance for net loss because of the uncertainty around certain items that may impact net loss that are not within its control or cannot be reasonably predicted without unreasonable effort.
We use adjusted EBITDA internally because we believe these metrics provide useful supplemental information in assessing our operating performance reported in accordance with GAAP. We believe adjusted EBITDA may enhance an evaluation of our operating performance because it excludes the impact of prior decisions made about capital investment, financing, investing and certain expenses we believe are not indicative of our ongoing performance. However, this non-GAAP financial measure may be different from non-GAAP financial measures used by other companies, even when the same or similarly titled terms are used to identify such measures, limiting their usefulness for comparative purposes. Accordingly, investors should not place undue reliance on non-GAAP financial measures.
This non-GAAP financial measure is not meant to be considered in isolation or used as a substitute for net loss reported in accordance with GAAP, should be considered in conjunction with our financial information presented in accordance with GAAP, has no standardized meaning prescribed by GAAP, is unaudited, and is not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that we may exclude for purposes of this non-GAAP financial measure, and we may in the future cease to exclude items that we have historically excluded for purposes of this non-GAAP financial measure. Likewise, we may determine to modify the nature of adjustments to arrive at this non-GAAP financial measure.
About Exagen
Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California.
For more information, please visit Exagen.com @ExagenInc
Forward Looking Statements
Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Exagen’s goals, strategies and ambitions; the potential utility and effectiveness of Exagen’s services and testing solutions; potential shareholder value and growth; preliminary financial information as of and for December 31, 2023; and guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 20, 2023 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact: ir@exagen.com
What are Exagen Inc.'s (XGN) preliminary unaudited financial results for the full year ended December 31, 2023?
Exagen Inc. reported a record AVISE® CTD testing volume of approximately 137,000 units and a cash balance of $36.5 million as of December 31, 2023.
What is Exagen Inc.'s (XGN) full-year 2023 total revenue guidance?
Exagen Inc. reaffirms its full-year 2023 total revenue guidance of at least $50 million.
What is Exagen Inc.'s (XGN) full-year 2023 non-GAAP adjusted EBITDA guidance?
Exagen Inc. reaffirms its full-year 2023 non-GAAP adjusted EBITDA guidance of approximately negative $20 million.
What is the cautionary note regarding Exagen Inc.'s (XGN) select preliminary unaudited financial results?
The company's financial closing procedures with respect to the estimated financial data provided above are not yet complete, and the final results may vary from the preliminary results presented.
What is the non-GAAP financial measure used in Exagen Inc.'s (XGN) press release?
The press release contains the non-GAAP financial measure adjusted EBITDA, which is not calculated in accordance with GAAP.
